摘要
目的观察长春地辛治疗原发性免疫性血小板减少症的临床有效性,找出其适应证。方法2015年1月至2019年5月我院收治的原发性免疫性血小板减少症患者30例,所有患者选用长春地辛治疗,根据疗效将其分为2组,治疗有效组16例(53.3%),无效组14例(46.7%),分析两组在性别构成、年龄、病程(新诊断;持续性;慢性)、抗核抗体阳性率及既往激素和(或)丙种球蛋白治疗无效等方面对长春地辛疗效有无影响。同时分析两组患者在长春地辛治疗前单核细胞计数、血小板计数、血小板宽度、大血小板比率及骨髓巨核细胞上的差异。结果治疗无效组抗核抗体阳性率高于有效组(P<0.05),治疗有效组血小板宽度(17.42±3.87)、大血小板比率(43.40±9.22)值均较无效组显著升高(P<0.05)。结论长春地辛治疗ITP在抗核抗体阴性、大血小板比率及血小板宽度显著升高者有较好的疗效,无严重不良反应,且骨髓巨核细胞数量不影响最终治疗。
Objective To observe the efficacy of vindesine in the treatment of primary immune thrombocytopenia and find out the incidence.Methods Totally 30 patients with primary immune thrombocytopenia in our hospital from January 2015 to May 2019 were divided into two groups according to the curative effect:effective group(n=16)and ineffective group(n=14).The effect of age,gender ratio,duration of disease,positive rate of anti-nuclear antibodies,no response to corticosteroids and/or intravenous immunoglobulins(IVIG)on the efficacy of vindesine was observed.The monocyte count,platelet count,P-LCR,PDW and the number of bone marrow megakaryocyte between the two groups were compared.Results The positive rate of antinuclear antibody in ineffective group was higher than that in effective group(P<0.05).The PDW(17.42±3.87)and P-LCR(43.40±9.22)in effective group were significantly higher than those in ineffective group(P<0.05).Conclusion Vindesine is effective in the treatment of ITP patients with negative anti-nuclear antibody and increased levels of PDW and P-LCR,no serious adverse reactions is found.The number of megakarocytes dose not affect the therapeutic effect.
作者
潘旭旭
王弘
PAN Xu-xu;WANG Hong(Department of Pediatric Hematology,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处
《实用药物与临床》
CAS
2020年第3期217-220,共4页
Practical Pharmacy and Clinical Remedies
